Cannabis and Crohn's Disease
Cannabis reliably improves Crohn's symptoms in small trials but has not been shown to heal the underlying inflammation.
Cannabis is one of the better-studied complementary treatments for Crohn's, and the symptom story is real: patients in small randomized trials feel better, eat more, sleep more, and use fewer steroids. But here's the catch the dispensary won't tell you — every well-designed study that looked at actual gut inflammation (CRP, calprotectin, endoscopy) found cannabis did *not* heal the bowel. So it's a good symptom tool, possibly a steroid-sparer, and not a disease-modifying drug. Treat it that way.
Not Medical Advice
This article is not medical advice. Crohn's disease is a serious, progressive condition that can cause bowel damage, fistulas, and surgery if undertreated. Do not substitute cannabis for therapy prescribed by a gastroenterologist. Talk to your IBD team before adding cannabis, especially if you take biologics, immunomodulators, or steroids. The information below summarizes published research as of the most recent reviews the author can verify; it is not personalized guidance.
Plain-Language Summary
Crohn's disease is a chronic inflammatory disease of the gut. The intestinal lining contains cannabinoid receptors (CB1 and CB2), and the body makes its own cannabinoids that help regulate gut motility, pain signaling, and inflammation [1][2]. That biology is why researchers got interested in cannabis for Crohn's in the first place.
When actually tested in humans, the pattern is consistent across multiple small trials: patients feel meaningfully better, but their gut doesn't look better on a scope or on blood tests [3][4][5]. So cannabis appears to be a symptom-control tool, not a cure or a disease-modifier. Whether that's good enough depends on your situation — some patients in remission with leftover symptoms benefit a lot; patients with active, damaging inflammation still need standard therapy.
What Probably Works
Symptom relief and quality of life. In a placebo-controlled trial by Naftali and colleagues (2013), 21 patients with active Crohn's who had failed standard therapy smoked THC-rich cannabis or placebo cigarettes for 8 weeks. The cannabis group had large improvements in the Crohn's Disease Activity Index (CDAI), pain, appetite, and sleep [3] [evidence:moderate]. A later trial of CBD-rich cannabis oil (not THC-dominant) showed similar symptom and quality-of-life benefits despite no change in inflammatory markers [4] [evidence:moderate].
Reduced reliance on other medications. In the 2013 trial, 5 of 11 cannabis patients achieved clinical remission by CDAI score, and several reduced or stopped steroids [3] Weak / limited. Observational and survey studies of IBD patients echo this pattern of reduced opioid and steroid use [6] Weak / limited.
Appetite and weight. THC is a reliable appetite stimulant, which matters in Crohn's where malnutrition and weight loss are common [7] [evidence:strong for appetite stimulation generally; moderate for Crohn's specifically].
What Might Work
Steroid-sparing effect. Suggested by trial data and surveys but never tested as a primary outcome in an adequately powered study [3][6] Weak / limited.
CBD alone (without THC). A small RCT of purified CBD (10 mg twice daily) in Crohn's showed no benefit over placebo, but the dose was likely too low [8] [evidence:weak / probably underdosed]. Higher-dose CBD-rich whole-plant oil did help symptoms in a separate trial [4]. The honest read: CBD might contribute, but the THC component appears to do most of the symptomatic heavy lifting.
Post-operative outcomes and fistula healing. Biologically plausible from CB2-receptor work in animals [2], but human evidence is essentially absent No data.
What Doesn't Work or Has Weak Evidence
Mucosal healing. This is the headline finding people skip. In the Naftali trials, CRP, fecal calprotectin, and endoscopic scores did not improve with cannabis, even when patients felt dramatically better [3][4] [evidence:moderate against]. In modern IBD care, mucosal healing — not just symptom control — is the treatment target because ongoing silent inflammation damages the bowel.
Cannabis as monotherapy for moderate-to-severe Crohn's. No evidence supports this, and given the lack of mucosal healing, it is not a reasonable substitute for biologics, immunomodulators, or aminosalicylates in active disease [3][4][5] [evidence:none for monotherapy].
'Indica is better for Crohn's' / strain-specific claims. Folklore. There is no controlled evidence that any particular cultivar or terpene profile outperforms another for IBD [evidence:none / folklore].
Smoked cannabis post-surgery. A retrospective study found heavy cannabis users with IBD had higher rates of surgery and complications, though confounding by disease severity is likely [9] Disputed.
What We Don't Know
- Whether cannabis changes long-term disease progression, bowel damage, or surgery rates (no long-term RCTs).
- Optimal cannabinoid ratio, dose, and route. Existing trials used smoked flower or oils; vaporized and oral preparations have not been compared head-to-head in Crohn's.
- Whether cannabis interacts meaningfully with biologics (infliximab, adalimumab, ustekinumab, vedolizumab). Pharmacokinetic data is limited.
- Whether the symptomatic-improvement-without-mucosal-healing pattern reflects a true analgesic/anti-nausea effect masking ongoing inflammation — a real concern raised by IBD specialists [5][10].
- Pediatric use: essentially unstudied and not recommended outside research settings.
Comparison with Standard Treatments
Standard Crohn's therapy is built around inducing and maintaining mucosal healing: corticosteroids (short-term induction), immunomodulators (azathioprine, methotrexate), biologics (anti-TNF agents, anti-integrins, anti-IL-12/23), and small molecules (JAK inhibitors). These have been shown in large RCTs to heal the gut lining and reduce surgeries [10] Strong evidence.
Cannabis has not been shown to do any of that. Where it fits, based on current data, is as an add-on for symptom control — pain, nausea, appetite, sleep, and quality of life — in patients whose underlying disease is being managed (or attempted to be managed) with standard therapy [3][4][6]. Some IBD specialists view it as a reasonable alternative to opioids for chronic Crohn's-related pain given the comparatively better safety profile [evidence:weak but plausible].
For more on the related condition, see Cannabis and Ulcerative Colitis and Cannabis and Chronic Pain.
Risks and Cautions
- Symptom masking. The biggest IBD-specific risk: feeling better while inflammation silently damages the bowel. Continue monitoring with your GI team (calprotectin, scopes) regardless of how good you feel [5][10].
- Cannabis use disorder. Roughly 1 in 10 adult users develop dependence; higher with daily use and high-THC products [11] Strong evidence.
- Cognitive and psychiatric effects. THC can worsen anxiety and, in vulnerable people, precipitate psychosis [11] Strong evidence.
- Drug interactions. CBD inhibits cytochrome P450 enzymes (especially CYP3A4 and CYP2C19) and can raise levels of co-administered drugs; this matters for tacrolimus, warfarin, some antiepileptics, and possibly some IBD medications [12] [evidence:strong for the pharmacology, moderate for clinical significance in IBD].
- Smoking-related harm. Smoked cannabis irritates airways; vaporization or oral routes are preferable for chronic medical use [11].
- Hyperemesis syndrome. Paradoxical severe vomiting in heavy chronic users — easily mistaken for a Crohn's flare [13] Strong evidence.
Sources
- Peer-reviewed Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & Therapeutics. 2010;126(1):21-38.
- Peer-reviewed Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129(2):437-453.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn's disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology. 2013;11(10):1276-1280.
- Peer-reviewed Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial. Journal of Crohn's and Colitis. 2021;15(11):1799-1806.
- Peer-reviewed Kafil TS, Nguyen TM, MacDonald JK, Chande N. Cannabis for the treatment of Crohn's disease. Cochrane Database of Systematic Reviews. 2018;11:CD012853.
- Peer-reviewed Ravikoff Allegretti J, Courtwright A, Lucci M, Korzenik JR, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflammatory Bowel Diseases. 2013;19(13):2809-2814.
- Peer-reviewed Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behavioural Pharmacology. 2005;16(5-6):297-313.
- Peer-reviewed Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn's disease, a randomized controlled trial. Digestive Diseases and Sciences. 2017;62(6):1615-1620.
- Peer-reviewed Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn's disease. Inflammatory Bowel Diseases. 2014;20(3):472-480.
- Peer-reviewed Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2020;14(1):4-22.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017. ↗
- Peer-reviewed Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. Journal of Clinical Medicine. 2019;8(7):989.
- Peer-reviewed Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment—a systematic review. Journal of Medical Toxicology. 2017;13(1):71-87.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.
Related
- Cannabis and Chronic Pain — What the evidence actually says about cannabis for long-term pain, separated from the mark...
- Cannabis and Ulcerative Colitis — What the evidence actually says about using cannabis for ulcerative colitis symptoms, remi...